Literature DB >> 30882236

The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.

Subodh Verma1, John J V McMurray2.   

Abstract

Entities:  

Keywords:  Editorials; SGLT2 inhibitors; diabetes mellitus; heart failure

Mesh：

Substances：

Year:  2019        PMID： 30882236     DOI： 10.1161/CIRCULATIONAHA.119.040514

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

1.  Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.

Authors:  Anna Norhammar; Johan Bodegard; Thomas Nyström; Marcus Thuresson; Klas Rikner; David Nathanson; Jan W Eriksson
Journal:  Diabetes Obes Metab       Date:  2019-08-26       Impact factor: 6.577

Review 2.  Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Diabetol Int       Date:  2020-06-11

Review 3.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

4.  Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.

Authors:  Bryce C Simes; Gordon G MacGregor
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-14       Impact factor: 3.168

Review 5.  Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.

Authors:  Masanori Wakisaka; Masahiro Kamouchi; Takanari Kitazono
Journal:  Int J Mol Sci       Date:  2019-11-12       Impact factor: 5.923

Review 6.  Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis.

Authors:  Milijana Janjusevic; Alessandra Lucia Fluca; Giulia Gagno; Alessandro Pierri; Laura Padoan; Annamaria Sorrentino; Antonio Paolo Beltrami; Gianfranco Sinagra; Aneta Aleksova
Journal:  Int J Mol Sci       Date:  2022-02-20       Impact factor: 5.923

Review 7.  Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update.

Authors:  Ioanna Koniari; Dimitrios Velissaris; Nicholas G Kounis; Eleni Koufou; Eleni Artopoulou; Cesare de Gregorio; Virginia Mplani; Themistoklis Paraskevas; Grigorios Tsigkas; Ming-Yow Hung; Panagiotis Plotas; Vaia Lambadiari; Ignatios Ikonomidis
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

Review 8.  Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure.

Authors:  Mieczysław Dutka; Rafał Bobiński; Izabela Ulman-Włodarz; Maciej Hajduga; Jan Bujok; Celina Pająk; Michał Ćwiertnia
Journal:  Heart Fail Rev       Date:  2020-11-04       Impact factor: 4.214

9.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Diabetes       Date:  2020-10-26       Impact factor: 9.461

Review 10.  The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Authors:  Emily Brown; John P H Wilding; Uazman Alam; Thomas M Barber; Janaka Karalliedde; Daniel J Cuthbertson
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.